COMPARE
Bandhan Financial Services Fund - Direct Plan - Growth vs Invesco India Pharma and Healthcare Fund - Direct Plan - Growth
Bandhan Financial Services Fund and Invesco India Pharma and Healthcare Fund are both in the Sectoral Fund category, from Bandhan AMC Limited and Invesco Asset Management (India) Private Limited respectively. Invesco India Pharma and Healthcare Fund has the lower expense ratio. See the full table and FAQ below for the complete real-data comparison.
Basics
Invesco India Pharma and Healthcare Fund has the lower direct-plan expense ratio, by 0.41 percentage points.
| Bandhan Financial Services Fund - Direct Plan - Growth | Invesco India Pharma and Healthcare Fund - Direct Plan - Growth | |
|---|---|---|
| Category | Sectoral Fund | Sectoral Fund |
| AMC | Bandhan AMC Limited | Invesco Asset Management (India) Private Limited |
| Benchmark | Nifty Financial Services TRI | BSE Healthcare TRI |
| NAV | ₹14.484 (2026-10-28) | ₹9.5 (2026-10-28) |
| AUM | ₹1,027.021 Cr | - |
| Expense Ratio (Direct) | 1% | 0.59% |
| Inception | 2023-07-10 | 2026-08-18 |
Returns
This fund is less than a year old, so there is not yet enough history to calculate rolling returns.
Risk Metrics
This fund is less than three years old, so a three-year risk history does not exist yet.
Portfolio Analytics
Invesco India Pharma and Healthcare Fund carries the higher portfolio P/E ratio (a rougher proxy for how richly the underlying holdings are valued) - see the table below for the full comparison.
Punji Fund Health Score
Invesco India Pharma and Healthcare Fund has the stronger Punji Quality grade of the two.
Frequently asked questions
Which has a lower expense ratio, Bandhan Financial Services Fund or Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund's direct-plan expense ratio is 0.41 percentage points lower than Bandhan Financial Services Fund's. Over long holding periods, a persistent expense-ratio gap compounds into a materially different final corpus even if the two funds' gross returns are similar - it's one of the few fund attributes you can compare with total certainty upfront, unlike future returns, since the fee is contractually fixed rather than a historical estimate.
Why don't Bandhan Financial Services Fund and Invesco India Pharma and Healthcare Fund show risk metrics like Sharpe ratio or alpha?
This fund is less than three years old, so a three-year risk history does not exist yet. This is a deliberate methodology choice, not missing data - risk metrics like alpha and Sharpe ratio are most meaningful for actively-managed funds where a manager makes decisions that can add or subtract value versus a benchmark. For a fund that mechanically tracks an index, the equivalent useful metric is tracking error (how closely it follows its index), not alpha.
Which fund has a longer track record, Bandhan Financial Services Fund or Invesco India Pharma and Healthcare Fund?
Bandhan Financial Services Fund launched on 2023-07-10, making it older than Invesco India Pharma and Healthcare Fund (launched 2026-08-18). A longer track record means more real market cycles (bull runs, corrections, rate cycles) the fund has actually navigated, which is useful context for judging consistency - but it isn't a guarantee of future performance, and a newer fund isn't automatically worse, especially if it's run by an experienced manager or team with a track record at a prior fund.
Data as of 2026-10-29. Source: AMFI disclosures via Punji. Not investment advice.